12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Natpara: Phase III data

The double-blind, U.S. Phase III RELAY trial in 46 patients showed that 18% of patients receiving 25 µg Natpara and 25% of patients receiving 50 µg Natpara achieved the primary endpoint of a reduction in daily oral calcium supplementation to <=500 mg and daily supplemental calcitriol to <=25 µg while maintaining albumin-corrected total serum calcium >=7.5 mg/dL at week 8. Additionally, 9% of patients receiving 25 µg Natpara and 29% of patients receiving 50 µg Natpara met the secondary endpoint of...

Read the full 384 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >